Eculizumab for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Randomized-Controlled Trial.

被引：0
|
作者：
Kulkarni, S. [1 ]
Kirkiles-Smith, N. [2 ]
Deng, Y. [3 ]
Formica, R. [4 ]
Gilbert, M. [5 ]
Broeckner, V. [6 ]
Bow, L. [1 ]
Pober, J. [2 ]
机构：
[1] Yale Univ, Surg, New Haven, CT USA
[2] Yale Univ, Immunobiol, New Haven, CT USA
[3] Yale Sch Publ Hlth, Yale Ctr Analyt Sci, New Haven, CT USA
[4] Yale Univ, Med, New Haven, CT USA
[5] Yale Univ, Pathol, New Haven, CT USA
[6] Univ Cambridge, Histopathol, Cambridge, England
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2016年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A222
引用
收藏
页码：475 / 476
页数：2
相关论文
共 50 条
  • [41] ECULIZUMAB IN PREVENTION OF ACUTE ANTIBODY-MEDIATED REJECTION IN SENSITIZED DECEASED-DONOR KIDNEY TRANSPLANT RECIPIENTS: 1-YEAR OUTCOMES
    Glotz, Denis
    Russ, Graeme
    Rostaing, Lionel
    Legendre, Christophe
    Chadban, Steven
    Grinyo, Josep Maria
    Mamode, Nizam
    Tufveson, Gunnar
    Couzi, Lionel
    Rigotti, Paolo
    Lebranchu, Yvon
    Sandrini, Silvio
    Marks, William
    TRANSPLANT INTERNATIONAL, 2015, 28 : 119 - 119
  • [42] PNEUMOCOCCAL AND TETANUS VACCINATION IN TACROLIMUS TREATED KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT MYCOPHENOLATE MOFETIL: A RANDOMIZED-CONTROLLED TRIAL
    de Weerd, Annelies
    Verschragen, Marieken J.
    van Gestel, Judith A.
    Dik, Wim A.
    Betjes, Michiel
    TRANSPLANT INTERNATIONAL, 2019, 32 : 417 - 417
  • [43] Mesangiolysis in Chronic Active Antibody-mediated Rejection in Kidney Transplant Biopsies
    Suto, Yuki
    Oguchi, Hideyo
    Tochigi, Naobumi
    Mikami, Tetuo
    Shinoda, Kazunobu
    Honda, Kazuho
    Kounoue, Noriyuki
    Hashimoto, Junya
    Muramatsu, Masaki
    Itabashi, Yoshihiro
    Sakai, Ken
    NEPHRON, 2023, : 14 - 21
  • [44] COMBINATION THERAPY OF RITUXIMAB AND INTRAVENOUS IMMUNOGLOBULIN AS AN EFFECTIVE TREATMENT FOR CHRONIC ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
    Park, Woo Yeong
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [45] A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
    Doberer, Konstantin
    Duerr, Michael
    Halloran, Philip F.
    Eskandary, Farsad
    Budde, Klemens
    Regele, Heinz
    Reeve, Jeff
    Borski, Anita
    Kozakowski, Nicolas
    Reindl-Schwaighofer, Roman
    Waiser, Johannes
    Lachmann, Nils
    Schranz, Sabine
    Firbas, Christa
    Muehlbacher, Jakob
    Gelbenegger, Georg
    Perkmann, Thomas
    Wahrmann, Markus
    Kainz, Alexander
    Ristl, Robin
    Halleck, Fabian
    Bond, Gregor
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 708 - 722
  • [46] Potential urinary extracellular vesicle protein biomarkers of chronic active antibody-mediated rejection in kidney transplant recipients
    Jung, Hee-Yeon
    Lee, Chan-Hyeong
    Choi, Ji-Young
    Cho, Jang-Hee
    Park, Sun-Hee
    Kim, Yong -Lim
    Moon, Pyong-Gon
    Baek, Moon -Chang
    Park, Jae Berm
    Kim, Yeong Hoon
    Chung, Byung Ha
    Lee, Sang-Ho
    Kim, Chan-Duck
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2020, 1138
  • [47] GRAFT SURVIVAL OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS: A SINGLE-CENTER STUDY
    Kaeoperm, Pichaya
    Homkrailas, Piyavadee
    NEPHROLOGY, 2023, 28 : 77 - 77
  • [48] Eculizumab for the Treatment of Antibody Mediated Rejection in Kidney Transplant Recipients: A Single Center Experience.
    Chi, A.
    Phillips, J.
    Quan, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 509 - 509
  • [49] COMBINATION THERAPY OF RITUXIMAB AND INTRAVENOUS IMMUNOGLOBULIN AS AN EFFECTIVE TREATMENT FOR CHRONIC ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
    Park, Woo Yeong
    Yeo, Sang Mok
    Park, Hayeon
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    TRANSPLANT INTERNATIONAL, 2017, 30 : 527 - 527
  • [50] BORTEZOMIB IN LATE ANTIBODY-MEDIATED KIDNEY TRANSPLANT REJECTION - A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL (BORTEJECT STUDY)
    Eskandary, F-A.
    Regele, H.
    Bond, G.
    Kozakowski, N.
    Wahrmann, M.
    Hidalgo, L.
    Haslacher, H.
    Kaltenecker, C.
    Aretin, M-B.
    Oberbauer, R.
    Reeve, J.
    Halloran, P.
    Boehmig, G.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 12 - 13
12345